Brief: Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven

Carlyle

Tue 10:14

Nov 3 (Reuters) - Carlyle CG.O and PAI Partners have agreed to sell pharmaceuticals company Theramex to rival private equity company Cinven, the companies announced on Tuesday.

• London-headquartered company Theramex is a leading global specialty pharmaceutical company focused on women's health.
• Theramex offers a diversified portfolio of treatments across menopause, osteoporosis, contraception, uterine health and fertility.
• The companies did not disclose the financial terms of the transaction, although the Financial Times reported earlier that the sale deal was worth 2.6 billion euros ($2.9 billion).
• "With Cinven, we have the right partner for our next chapter, and we share an ambition to become the global leader in women's health," said Theramex CEO Robert Stewart in a statement.
($1 = 0.8937 euros)

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))